Fenofibrate Attenuates Renal Tubular Cell Apoptosis by Up-Regulating MCAD in Diabetic Kidney Disease
Chao Tang,Xiaoqing Deng,Jingru Qu,Yahui Miao,Lei Tian,Man Zhang,Xiaoyu Li,Bei Sun,Liming Chen
DOI: https://doi.org/10.2147/DDDT.S405266
2023-05-18
Abstract:Chao Tang, 1, 2, &ast Xiaoqing Deng, 1, &ast Jingru Qu, 1 Yahui Miao, 1 Lei Tian, 1 Man Zhang, 1 Xiaoyu Li, 1 Bei Sun, 1 Liming Chen 1 1 NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, 300134, People's Republic of China; 2 The Affiliated Huzhou Hospital, Zhejiang University School of Medicine (Huzhou Central Hospital), Huzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Liming Chen; Bei Sun, No. 6 North Huanrui Road, Beichen District, Tianjin, People's Republic of China, Email ; Background: Diabetic kidney disease (DKD) is a major diabetic microvascular complication. Fatty acid-induced lipotoxicity and apoptosis were associated with the exacerbation of DKD. However, the association of lipotoxicity with renal tubular apoptosis and the effects of fenofibrate on DKD are not fully understood. Methods: Eight-week-old db/db mice were given fenofibrate or saline by gavage for 8 weeks. Human kidney proximal tubular epithelial (HK2) cells stimulated with palmitic acid (PA) and high glucose (HG) were used as a model of lipid metabolism disorders. Apoptosis was assessed with or without fenofibrate. The AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) and AMPK inhibitor Compound C were used to determine the involvement of AMPK and Medium-chain acyl-CoA dehydrogenase (MCAD) in the regulation of lipid accumulation by fenofibrate. MCAD silencing was achieved by small interfering RNA (siRNA) transfection. Results: Fenofibrate reduced triglyceride (TG) content and lipid accumulation in DKD. Importantly, renal function and tubular cell apoptosis were significantly improved by fenofibrate. Fenofibrate reduced apoptosis, accompanied by increased activation of the AMPK/FOXA2/MCAD pathway. MCAD silencing resulted in apoptosis and lipid accumulation despite fenofibrate treatment. Conclusion: Fenofibrate improves lipid accumulation and apoptosis through the AMPK/FOXA2/MCAD pathway. MCAD may be a potential therapeutic target of DKD, and the use of fenofibrate as a treatment for DKD warrants further study. Keywords: fenofibrate, diabetic kidney disease, renal tubular cell, apoptosis, lipid accumulation, MCAD Diabetic kidney disease (DKD) is a typical complication of diabetes mellitus, associated with higher mortality and morbidity, and is a major cause of end-stage renal disease (ESRD). 1 DKD is clinically characterized by albuminuria and a progressive decline in kidney function. 2 Although glomerular pathology is thought to be the primary target of diabetic injury, it has been well documented that tubulointerstitial injury plays an important role in the progression of DKD. 3 Renal tubular cell apoptosis is clearly recognized as a key pathogenesis of chronic kidney injury and is associated with the progression of renal fibrosis. 4 Previous work has shown that high glucose (HG) conditions induce apoptosis of renal tubular epithelial cells in vitro and in vivo. 5,6 Abnormal lipid flow and lipid deposition have been identified as major risk factors for the progression of diabetes. In recent years, it has been increasingly recognized that lipid accumulation is also largely involved in the development of DKD. 7 Lipid accumulation in the kidney causes lipotoxicity, which may lead to kidney damage and further transform into kidney fibrosis. 5,6 Medium-chain acyl-CoA dehydrogenase (MCAD) is a mitochondrial enzyme involved in the β-oxidation of medium-chain fatty acids (MCFA). 8 MCAD deficiency leads to lipid deposition in several tissues, but its role in DKD remains unclear. 9 AMP-activated protein kinase (AMPK), a serine/threonine kinase, acts as an energy sensor in the homeostasis of carbohydrate and lipid metabolism. 10,11 Downregulation of AMPK and tubular damage were observed in DKD. 12 Studies have shown that AMPK can inhibit forkhead box A2 (FOXA2) nuclear excretion and reduce lipid deposition. 10 FOXA2 is a transcription factor belonging to the forkhead box family that plays a regulatory role in the maintenance of glucose and lipid homeostasis. 13,14 FOXA2 promotes MCAD transcription by binding upstream of the MCAD promoter. 15 FOXA2 activates the transcriptional program of lipid metabolism under normal conditions. In insulin-resistant mice, plasma insulin inhibits FOXA2 by nuclear exclusion and FOXA -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal